Nucana Plc (NCNA) has released an update.
NuCana plc showcased the therapeutic potential of NUC-7738 at the AACR 2024 Annual Meeting, demonstrating its ability to reprogram cancer cell lipid metabolism and alter ribosome biogenesis, which are vital for tumor growth and survival. These findings suggest NUC-7738 could make tumors less aggressive and enhance cancer cell death. The data support the ongoing clinical development of NUC-7738, reinforcing its promise as a transformative cancer treatment, particularly in combination with pembrolizumab.
For further insights into NCNA stock, check out TipRanks’ Stock Analysis page.
